<code id='2054AF41BA'></code><style id='2054AF41BA'></style>
    • <acronym id='2054AF41BA'></acronym>
      <center id='2054AF41BA'><center id='2054AF41BA'><tfoot id='2054AF41BA'></tfoot></center><abbr id='2054AF41BA'><dir id='2054AF41BA'><tfoot id='2054AF41BA'></tfoot><noframes id='2054AF41BA'>

    • <optgroup id='2054AF41BA'><strike id='2054AF41BA'><sup id='2054AF41BA'></sup></strike><code id='2054AF41BA'></code></optgroup>
        1. <b id='2054AF41BA'><label id='2054AF41BA'><select id='2054AF41BA'><dt id='2054AF41BA'><span id='2054AF41BA'></span></dt></select></label></b><u id='2054AF41BA'></u>
          <i id='2054AF41BA'><strike id='2054AF41BA'><tt id='2054AF41BA'><pre id='2054AF41BA'></pre></tt></strike></i>

          explore

          explore

          author:knowledge    Page View:9
          Matts Take Column Illustration
          Molly Ferguson for STAT

          American medicine is a tragic paradox. An example: Cancer patients are likely dying as a result of drug shortages that occurred partly because generic chemotherapies have been allowed to become too cheap. At the same time, other patients are suffering, and perhaps dying, because the financial burden brought on by the expensive medicines they need is too high.

          Sit with that like a terrible Zen koan: Medicines are both too cheap and too expensive.

          advertisement

          How is that possible? A lot of it goes back to the 1984 Hatch-Waxman Act, which set up the ecosystem that determines the process by which drugs go from being expensive brands to cheap generics in the U.S.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Kristina Burow of ARCH Venture Partners shares her next big bets STAT
          Kristina Burow of ARCH Venture Partners shares her next big bets STAT

          AlexHogan/STATKristinaBurowhasawell-trainedeye.That’strueofherworkatARCHVenturePartners,oneofthedrug

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

          ADAMFEUERSTEIN/STATCHICAGO—CorbusPharmaceuticalsisthesecondbest-performingbiotechstockthisyear,thank